Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 10/20 | 0.56 |
| ▸ | ESR1 | P03372 | 2/20 | 0.56 |
| ▸ | GUSB | P08236 | 4/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14458014 | 0.95 | ESR2 (0.51) | ESR2ESR1GUSBPDE4APDE4B | |
| SCHEMBL9800296 | 0.89 | ESR2 (0.49) | ESR2ESR1GUSBPDE4APDE4B | |
| SCHEMBL620339 | 0.82 | ESR2 (0.44) | ESR2ESR1GUSBKMT2A | |
| SCHEMBL29743248 | 0.82 | ESR2 (0.44) | ESR2ESR1GUSBKMT2A | |
| SCHEMBL23878342 | 0.81 | TDP1 (0.46) | PDE4APDE4BPDE4CPDE4DHDAC2 | |
| SCHEMBL22201142 | 0.81 | TP53 (0.51) | ESR2ESR1PDE4APDE4BPDE4C | |
| SCHEMBL22190402 | 0.81 | PDE4A (0.44) | ESR2ESR1GUSBPDE4APDE4B | |
| SCHEMBL22201146 | 0.81 | ALDH1A1 (0.54) | ESR2ESR1PDE4APDE4BPDE4C | |
| SCHEMBL22201140 | 0.81 | PDE4A (0.44) | ESR2ESR1GUSBPDE4APDE4B | |
| SCHEMBL22201147 | 0.81 | PDE4A (0.44) | ESR2ESR1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0671388-B1 | (Pyrrolidinyl)phenyl carbamates and intermediate compounds, processes for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1998-06-10 | — | — | EP | claimed |
| EP-0671388-A1 | (Pyrrolidinyl)phenyl carbamates and intermediate compounds, processes for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1995-09-13 | — | — | EP | claimed |
| US-20180338980-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-29 | — | — | US | disclosed |
| EP-3307715-A1 | AROMATIC SULFONAMIDE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2018-04-18 | — | — | EP | disclosed |
| CN-107848974-A | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2018-03-27 | — | — | CN | disclosed |
| WO-2016198374-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-15 | — | — | WO | disclosed |
| EP-2217592-A1 | BIPHENYL DERIVATIVES AS MODULATORS OF THE HISTAMINE-H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7659294-B2 | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists | MERCK & CO., INC. (US) | 2010-02-09 | — | — | US | disclosed |
| WO-2009058300-A1 | BIPHENYL DERIVATIVES AS MODULATORS OF THE HISTAMINE-H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090042954-A1 | 2-(Aryl)Azacyclylmethyl Carboxylates, Sulfonates, Phosphonates, Phosphinates and Heterocycles as S1p Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
| CN-101043887-A | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists | MERCK & CO INC (US) | 2007-09-26 | — | — | CN | disclosed |
| US-6274613-B1 | APPLYING COMPOUNDS SUCH AS A GAMMA-ETHOXY-GAMMA-BUTYROLACTAM TO PESTS AND/OR THEIR HABITATS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-08-14 | — | — | US | disclosed |
| EP-1121357-A1 | 2-HETARYL-3,4-DIHYDRO-2H-PYRROLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2001-08-08 | — | — | EP | disclosed |
| EP-1080072-A1 | 2-(2-CHLOROPHENYL)-3,4-DIHYDRO-2H-PYRROL DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2001-03-07 | — | — | EP | disclosed |
| EP-1077938-A1 | 2-(2-METHYLPHENYL)-3,4-DIHYDRO-2H-PYRROL DERIVATIVES | BAYER AG (DE) | 2001-02-28 | — | — | EP | disclosed |
| WO-2000021958-A1 | 2-HETARYL-3,4-DIHYDRO-2H-PYRROLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999059968-A1 | 2-(2-CHLOROPHENYL)-3,4-DIHYDRO-2H-PYRROL DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999059967-A1 | 2-(2-METHYLPHENYL)-3,4-DIHYDRO-2H-PYRROL DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-25 | — | — | WO | disclosed |
| EP-0942901-A1 | CYCLIC IMINES AS PESTICIDES | BAYER AG (DE) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022438-A1 | CYCLIC IMINES AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042954-A1 | 2-(Aryl)Azacyclylmethyl Carboxylates, Sulfonates, Phosphonates, Phosphinates and Heterocycles as S1p Receptor Antagonists | S1PR1, S1PR3, S1PR5 | ESR2 444/4885ESR1 819/4885GUSB 4594/4885 |
| US-20180338980-A1 | AROMATIC SULFONAMIDE DERIVATIVES | ARSA, SULT2A1, TPST2 | ESR2 1222/4885ESR1 1890/4885GUSB 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.